Newron Pharmaceuticals S.p.A. (NP5.F)

Compare

5.91

-0.41

(-6.49%)

As of 11:20:38 AM GMT+2. Market Open.

Newron Presents 2024 Financial Results and Provides 2025 Outlook

MILAN, April 01, 2025--Newron presents 2024 financial results and provides 2025 outlook

Business Wire 5 days ago

NWPHF
Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman

MILAN & MORRISTOWN, N.J., March 24, 2025--Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman

Business Wire 13 days ago

NWPHF
Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference

MILAN, Italy & MORRISTOWN, N.J., March 11, 2025--Newron to participate in a fireside chat at the 37th Annual ROTH Conference on Monday, March 17 at 11:30 am PDT.

Business Wire 26 days ago

NWPHF
Newron and Myung In Pharm Announce License Agreement for evenamide in South Korea

MILAN, Italy & MORRISTOWN, New Jersey & SEOUL, Republic of Korea, January 09, 2025--Newron and Myung In Pharm, South Korea's leading specialist CNS pharma company, announce license agreement for evenamide in South Korea.

Business Wire 2 months ago

NWPHF
Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories

MILAN & MORRISTOWN, N.J. & TOKYO, December 13, 2024--Newron and EA Pharma sign licence for evenamide in Japan & Asia. Newron to receive up to €117 million from upfront payments, milestones and royalties.

Business Wire 3 months ago

NWPHF
Newron presents H1 2024 results and provides business update

MILAN, September 19, 2024--Newron today announces its financial and operational results for the half year ended June 30, 2024, and provides an update on its business activities

Business Wire 6 months ago

NWPHF
Aligos Therapeutics Strengthens Board with Two New Independent Directors

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the appointment of Heather Preston, M.D. and Margarita Chavez, J.D. as Class II Independent Directors to the Board of Directors, effective August 7, 2024. Dr. Preston will join the Nominating and Corporate Gove

GlobeNewswire 7 months ago

ONTTF

OXFYY

NWPHF
Newron Pharmaceuticals Reports on Its 2024 Investor Day in New York City

MILAN & MORRISTOWN, N.J., June 25, 2024--Newron reports data from its 2024 Investor Day indicating evenamide would be uniquely effective in patients with treatment resistant schizophrenia

Business Wire 9 months ago

NWPHF
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City

MILAN & MORRISTOWN, N.J., June 18, 2024--Newron Pharmaceuticals to host its 2024 Investor Day on June 25, 2024, in New York City. Live webcast beginning at 9:00 AM EDT.

Business Wire 9 months ago

NWPHF
Newron Pharmaceuticals Will Host Its 2024 Investor Day on June 25 in New York City

MILAN & MORRISTOWN, N.J., June 05, 2024--Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City. New hope emerges for treatment-resistant schizophrenia.

Business Wire 9 months ago

NWPHF
Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients

MILAN, May 13, 2024--Newron reports new data from pivotal study 008A for chronic schizophrenia patients revealing clinically significant efficacy benefits over time.

Business Wire 10 months ago

NWPHF
Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients

MILAN, April 30, 2024--Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients

Business Wire 11 months ago

NWPHF
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

MILAN, April 08, 2024--Newron presents existing evenamide study 014/015 data and future clinical development outlook for evenamide at 2024 SIRS Congress in Florence, Italy

Business Wire 11 months ago

NWPHF

Performance Overview

Return	NP5.F	MSCI WORLD (^990100-USD-STRD)
YTD	-36.38%	-11.95%
1-Year	-28.71%	-3.76%
3-Year	+380.49%	+8.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Newron Pharmaceuticals S.p.A. (NP5.F)

Newron Presents 2024 Financial Results and Provides 2025 Outlook

Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman

Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference

Newron and Myung In Pharm Announce License Agreement for evenamide in South Korea

Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories

Newron presents H1 2024 results and provides business update

Aligos Therapeutics Strengthens Board with Two New Independent Directors

Newron Pharmaceuticals Reports on Its 2024 Investor Day in New York City

Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City

Newron Pharmaceuticals Will Host Its 2024 Investor Day on June 25 in New York City

Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients

Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

Performance Overview